Skip to main content

Safety and efficacy of a feed additive consisting of Limosilactobacillus reuteri (formerly Lactobacillus reuteri) DSM 32264 as a feed additive for cats (NBF Lanes s.r.l.)

  • 2022-08
  • EFSA Journal 20(8)
    • V. Bampidis
    • G. Azimonti
    • M. Bastos
    • Henrik Christensen
    • Birgit Dusemund
    • Mojca Fašmon Durjava
    • M. Kouba
    • M. López-Alonso
    • Secundino López Puente
    • F. Marcon
    • B. Mayo
    • A. Pechová
    • M. Petkova
    • F. Ramos
    • Yolanda Sanz
    • R. Villa
    • R. Woutersen
    • G. Martelli
    • M. Anguita
    • J. Galobart
    • J. Ortuño
    • J. Revez
    • Rosella Brozzi

Abstract

Following a request from the European Commission, EFSA was asked to deliver a scientific opinion on the efficacy of a product consisting of Limosilactobacillus reuteri (formerly Lactobacillus reuteri) DSM 32264 as a zootechnical additive for cats. The additive is a preparation of viable cells of L. reuteri DSM 32264 and it has not been previously authorised as a feed additive in the European Union. The additive is intended for use in complete feed for cats at a minimum inclusion level of 6 × 109 colony forming units (CFU) per animal and day. In a previous opinion, the FEEDAP Panel could not conclude on the efficacy of L. reuteri DSM 32264 for cats. The applicant has provided supplementary information to support the efficacy of the additive for cats. Based on the data provided, the FEEDAP Panel concluded that L. reuteri DSM 32264 has the potential to improve faecal consistency by reducing the moisture content of stools from cats receiving the additive at 1 × 1010 CFU/kg feed. However, the Panel had some reservations on the effects in the moisture content, which if maintained overtime, might cast doubts on the benefits on the long-term use of the additive since it could lead to constipation.

Keywords: Limosilactobacillus reuteri DSM 32264; NBF‐2; cats; efficacy; gut flora stabilisers; zootechnical additives.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Limosilactobacillus reuteri 1E1Improved Stool ConsistencyBeneficial
Moderate
Limosilactobacillus reuteri 1E1Increased Constipation RiskHarmful
Moderate
⬆ Back to top
Pillser
Supplement Research and Comparison Website: evidence-based information about supplements, their benefits, potential risks, and their efficacy.
Receive updates about our products, services, sales, and special offers. Unsubscribe anytime. See our Privacy Policy for details on how we handle your information.

Join Our Community

Use support@pillser.com to get in touch.